

30 May 2014

Extension of Rights Closing Date

Extension of Closing Date of Rights Issue

Resonance Health Limited (ASX: RHT) (Resonance or the Company), has extend the Closing Date of the entitlement offer to **5.00pm (Perth Time), Friday 13th June 2014** following the announcement of a trading halt.

Entitlement Offer


As announced on 10 April 2014 the non-renounceable entitlement offer will give existing eligible Resonance shareholders the opportunity to subscribe for one (1) New Share for every four (4) existing Resonance shares held at 5.00pm (AEDT) on 30 April 2014 (**Record Date**) at an Issue Price of \$0.05 per New Share. The Entitlement Offer will comprise the offer of approximately 92.7 million shares (**the Entitlement Offer Shares**) at the Issue Price to raise total proceeds of approximately \$4.6m before costs.

Shareholders may also elect to participate in the shortfall facility and apply for new shares in excess of their entitlement.

The revised timetable for the remaining dates is as follows:

Entitlement Offer Closing Date	13 June
Shares quoted on a deferred settlement basis	16 June
ASX notified of under subscriptions	17 June
Issue date/Shares entered into Shareholders' security holdings	19 June
Quotation of shares issued under the Entitlement offer	20 June

This timetable is indicative only and may be subject to change. Subject to the Corporations Act and ASX Listing Rules, Resonance reserves the right to vary the dates and times in conjunction with the Entitlement Offer, including the closing date, without prior notice.



If there is a shortfall in subscriptions under the Entitlement Offer, the Company reserves the right to place the shortfall shares at their discretion within three months of the closing date of the offer.

Azure Capital Ltd has been engaged as Lead Manager in relation to the Placement and Entitlement Offer.

For further information please contact:

Resonance Health

Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.